World's First Robotic Living-Donor Liver Transplant at Queen Mary Hospital: How 48 Robotic Microsurgery Procedures Are Rewriting the Limits of Precision Surgery in Hong Kong

HONG KONG — The single most demanding suture in modern surgery is roughly the width of a human hair. Microvascular anastomosis — the act of sewing two cut ends of a blood vessel back together — is performed on structures as fine as 0.1 to 0.3 mm, under a high-powered operating microscope, with sutures thinner than an eyelash. The surgeon must hold their hand steady for hours, maintain a fixed body position, and watch every stitch through a binocular eyepiece while the patient's breathing and heartbeat push the tissue around. Most surgical residents wash out of microsurgery training within their first year. The ones who don't typically end up at a handful of centers worldwide where the case volume is concentrated.

On June 24, 2026, a team from the University of Hong Kong's medical school (HKUMed) and Queen Mary Hospital (QMH) reported that they had performed the world's first robotic-assisted living-donor liver transplant — a global first that is unlikely to be matched any time soon by a center without a working robotic microsurgery program. The April 2026 liver transplant was the high-profile case in a series of 48 robotic-assisted microsurgical procedures the HKUMed team has completed at Queen Mary Hospital since introducing the clinical program in June 2025, all without long-term or post-operative complications. For international patients needing complex microvascular reconstruction after cancer resection, trans-hairline head-and-neck reconstruction, or living-donor liver transplantation in a setting where the anastomosis is too small for a human hand to do reliably, the HKUMed program is the only one in the world with this case volume and case mix as of mid-2026.

The story is also a continuation of a sixty-year arc. China has been the global center of microsurgery since 1966, when Chen Zhongwei at the Shanghai Sixth People's Hospital performed the world's first successful second-toe-to-thumb transplant, replanting a severed thumb using microvascular technique. The PLA military hospital system that grew out of that lineage trains more microsurgeons per year than the rest of the world combined. What HKUMed has done in the past thirteen months is layer a robotic platform on top of that inherited capability, and the early results suggest the platform is not just a marketing addition but a genuine change in what microsurgical teams can reliably accomplish.

What microsurgery is, and why it sits at the technical ceiling of operative surgery

Microsurgery is not a specialty so much as a technique applied across many of them. Plastic and reconstructive surgeons use it to reattach severed fingers and transplant toes to thumb stumps. Vascular surgeons use it for super-microsurgical lymphaticovenous anastomosis in lymphoedema. Head and neck surgeons use it to reconnect arteries and veins when removing a tumor would otherwise leave the patient disfigured. Transplant surgeons use it for living-donor liver and kidney transplantation, where the donor hepatic artery or renal artery is too small for a hand-sewn anastomosis to be reliably patent. The unifying feature is the operating field: the human eye unaided cannot see what the surgeon is doing. The surgeon looks through a binocular operating microscope, holds instruments that look like long tweezers with tips smaller than a pencil point, and sews with sutures that range from 8-0 (the suture strand is about 0.04 mm thick, thinner than a human hair) to 12-0 (used for lymphaticovenous anastomosis, where the vessel itself is barely visible).

The technical ceiling is set by three things. The first is hand tremor — every human hand has a physiological tremor of about 0.1 to 0.3 mm at rest, and the tremor worsens under fatigue, stress, or caffeine. At 0.1 mm operating field, that tremor is enough to misplace a stitch. The second is ergonomics — a microsurgeon performing a long anastomosis sits in a fixed posture, often leaning forward at an awkward angle to align the microscope, and the resulting neck, shoulder, and back strain cuts into the surgeon's effective working time. The third is anatomy — some operative sites (deep in the abdomen, deep in the neck, behind the ear, inside the chest) do not allow a comfortable angle for the surgeon's hands and the microscope simultaneously, which means the anastomosis has to be done by feel and approximation, not by direct vision.

The robotic microsurgical platform that HKUMed introduced in June 2025 attacks all three problems at once. Tremor is filtered out at the console by software that distinguishes the surgeon's intentional hand motion from physiological tremor and discards the latter. Motion scaling lets the surgeon move their hands 5x or 10x larger than the actual instrument tip, so a 2 mm hand motion becomes a 0.4 mm instrument motion. The seven-degrees-of-freedom micro-instruments can articulate inside the patient in ways a human wrist cannot, reaching anatomical sites that would be physically inaccessible to a hand-held instrument. And because the surgeon operates from a console that can be positioned anywhere in the room (or even in another city via a high-bandwidth connection), the ergonomics constraint collapses — the surgeon sits upright in a chair, looking at a 3D screen, with their hands on controls that feel like they are holding the instruments directly.

The 48 procedures: what was done, and what the early data show

The HKUMed clinical series, as reported on June 24, 2026, runs from the program's launch in June 2025 through the most recent procedure in June 2026. The case mix is dominated by three indication groups: living-donor liver transplantation (the highest-profile cases, including the April 2026 world-first robotic liver transplant), head-and-neck cancer reconstruction (with the trans-hairline approach that places the surgical incision inside the hair-bearing scalp rather than on the visible anterior neck), and post-tumor-extirpation reconstruction across multiple anatomical sites. Smaller-volume indications include lymphatic surgery for lymphoedema and trauma reconstruction.

The clinical outcomes, in the team's own words, are clean: every one of the 48 procedures was completed robotically without conversion to open or conventional microscopic technique, every anastomosis was patent at the end of the procedure, and no patient experienced a postoperative complication related to the use of the robotic platform during the follow-up window. In surgical series language, the conversion rate is zero and the major complication rate is zero. That is a remarkable result for a new surgical program, especially one operating at the technical ceiling of what any surgeon can do, and it is consistent with what the early Western robotic microsurgery programs (mostly in plastic surgery departments at academic medical centers in the United States, the Netherlands, and Belgium) have reported over the past five years.

The two highest-profile cases deserve specific mention.

The April 2026 world-first robotic living-donor liver transplant

Living-donor liver transplantation is a uniquely demanding microsurgical case. The donor operation removes a portion of a healthy person's liver (typically the right lobe for an adult recipient, or the left lateral segment for a pediatric recipient), and the recipient operation implants the donor graft by connecting the graft's hepatic artery, portal vein, hepatic vein, and bile duct to the recipient's remaining vasculature. The hepatic artery is the bottleneck: it is short, small-caliber (typically 2 to 4 mm in adults, smaller in children), and the patency of the anastomosis is critical for perfusion of the graft. A failed hepatic artery anastomosis is a catastrophic complication that typically requires re-transplantation.

The conventional approach at high-volume Western centers is to perform the hepatic artery anastomosis under the operating microscope with hand-sewn sutures — a 9-0 or 10-0 suture, on a vessel that is moving with each heartbeat and each breath of the patient. The HKUMed team performed the anastomosis robotically, with the robotic micro-instruments filtering out the cardiac pulsation and respiratory motion and allowing the surgeon to place each stitch precisely. The team has not yet released a peer-reviewed paper on the procedure; the announcement was made at the June 24, 2026 press briefing, and the full clinical paper is reportedly in preparation.

For liver transplantation, the broader implication is significant. Living-donor liver transplantation is the dominant form of pediatric liver transplantation worldwide and an important option for adult recipients in regions where deceased-donor organs are scarce. Hong Kong, mainland China, Japan, Korea, and Taiwan all rely heavily on living-donor liver transplantation because of the cultural and regulatory constraints on deceased donation. A robotic platform that allows the hepatic artery anastomosis to be done with greater precision and less surgeon fatigue could expand the pool of surgeons capable of performing the procedure, which would in turn expand access for patients.

The trans-hairline robotic head-and-neck reconstruction

The second world-first, performed in late 2025, is the trans-hairline approach to head-and-neck cancer reconstruction. Patients with head-and-neck cancer often require reconstruction after tumor removal to restore speech and swallowing. The conventional microvascular reconstruction uses an incision on the anterior (front) of the neck to access the recipient blood vessels that will supply the reconstructed tissue. That anterior incision leaves a conspicuous scar and, often, transects the dermal lymphatics that drain the face and neck, leading to lymphoedema (chronic swelling) that interferes with both appearance and function.

The HKUMed team's innovation is to reposition the incision into the posterior hairline — an area naturally concealed by hair, where the scar is invisible to anyone not specifically looking for it, and where the dermal lymphatics can be preserved. The technical challenge is that the working distance from the new incision to the recipient vessels is much longer, and the working space much tighter, than the conventional anterior approach. Manual microvascular anastomosis via the trans-hairline approach is so ergonomically difficult that only the most experienced microsurgeons can perform it, and even they typically have to work in non-physiological positions with poor visualization and no assistant help.

The robotic platform changes this. The extended reach of the seven-degrees-of-freedom robotic arms allows the surgeon to operate effectively in the confined posterior hairline space, with the same precision and ergonomics as a conventional anterior approach. The clinical outcomes reported so far are: every trans-hairline anastomosis has been patent, facial and neck lymphoedema has been minimal compared to the anterior approach, and the scar is concealed. The result, for international patients with head-and-neck cancer who would otherwise face a visible anterior neck scar for life, is a meaningfully better cosmetic and functional outcome.

The Chinese microsurgery lineage: from 1966 to 2026

The HKUMed program sits at the end of a longer arc that began in Shanghai in January 1966. Chen Zhongwei (陈中伟), a 37-year-old orthopedic surgeon at the Shanghai Sixth People's Hospital, was called to consult on a young factory worker named Wang Cunbo who had lost his right hand in a cutting machine accident and whose right thumb was still attached by a small strip of tissue. Working with colleagues from the Shanghai Ninth People's Hospital, Chen performed the world's first successful replantation of a completely severed limb — a hand, not just a digit — in a procedure that took about seven hours and required microsurgical anastomosis of arteries, veins, nerves, and tendons that had never before been reconnected in a living patient.

The international surgical community was stunned. Replantation had been attempted in animal models for two decades, but no human case had succeeded. Chen's procedure established the field of clinical microsurgery as it exists today. Within five years, replantation of fingers, hands, and limbs had spread from Shanghai to military hospitals across China, and from there to the rest of the world. Chen Zhongwei became known as the "father of replantation surgery," and the Chinese military hospital system — particularly the PLA's 401, 401 Hospital in Qingdao, the 89th Hospital in Weifang, the Zhongnan Hospital of Wuhan University, and the Huashan Hospital in Shanghai — became the global center of high-volume microsurgical training.

The technical lineage matters for the HKUMed story because the manual microsurgery skill set that the HKUMed team brings to the robotic platform is deeper, and more widely distributed across Chinese surgical training programs, than anywhere else in the world. A typical senior Chinese microsurgeon has personally performed more microvascular anastomoses than the entire surgical staff of most Western academic medical centers combined. When that level of manual skill is paired with a robotic platform, the achievable technical ceiling moves — not because the robot replaces the surgeon's hands, but because it removes the physical limitations (tremor, ergonomics, anatomical access) that prevented manual microsurgeons from reaching certain procedures.

The broader Chinese microsurgery ecosystem is large and structured. The Chinese Society of Reconstructive Microsurgery (中华医学会显微外科学分会) holds an annual meeting that draws more than 1,500 surgeons. The Chinese Journal of Microsurgery publishes roughly 400 peer-reviewed papers per year, mostly from Chinese surgical teams. The PLA General Hospital, the Fourth Military Medical University (Tangdu Hospital, where the 3D-printed PEEK extravascular stent program for nutcracker syndrome lives), the Huashan Hospital affiliated to Fudan University, and the Xiangya Hospital of Central South University all run high-volume microsurgery services. None of the Western academic medical centers that have introduced robotic microsurgery programs in the past five years has yet matched the manual microsurgery case volume of any one of those Chinese centers.

How the robotic platform works, in plain language

The robotic microsurgical platform is not the same as the da Vinci surgical robot that has been used for prostatectomy, hysterectomy, and other laparoscopic procedures since the early 2000s. The da Vinci platform is designed for general laparoscopic surgery at operating fields of 5 to 10 mm; its instruments are too large and its tremor filtration not fine-grained enough for microsurgical work at 0.1 to 0.3 mm. The dedicated microsurgery platform that HKUMed uses is built around micro-instruments that are roughly an order of magnitude smaller, with motion scaling that can reduce a 5 mm surgeon hand motion to a 0.5 mm instrument tip motion.

The surgeon sits at a console, looking at a high-definition 3D display that shows the operating field at high magnification. The surgeon's hands rest on ergonomic controllers that translate gross hand motion into precise instrument motion inside the patient. The system filters out physiological tremor at multiple levels (hand motion, controller input, and instrument output), so the effective tremor at the instrument tip is below 0.05 mm — below the resolution of what the human eye can see at operating microscope magnification. The seven-degrees-of-freedom micro-instruments can articulate in ways that a human wrist cannot, allowing the surgeon to place stitches at angles that would be physically impossible with a hand-held instrument.

The platform also separates the surgeon from the patient anatomically. The surgeon does not need to be at the bedside, which means the bedside team can position the patient in whatever orientation the procedure requires (often a steep Trendelenburg for pelvic surgery, or a lateral decubitus for liver surgery) without constraining the surgeon's posture. In the trans-hairline head-and-neck application, the surgeon operates from a console positioned behind the patient's head, while the bedside team manages the head positioning and the flap harvest.

For training, the platform is a step change. Manual microsurgery has a steep learning curve — the typical Western training pathway takes 7 to 10 years from medical school graduation to independent microvascular practice, and a meaningful fraction of trainees drop out along the way. The robotic platform's combination of tremor filtration, motion scaling, and ergonomic optimization shortens the effective learning curve by reducing the sources of variability that make manual microsurgery so unforgiving. The HKUMed team's explicit goal, as stated at the June 24 press briefing, is to use the robotic platform to "elevate more surgeons to a high level of competency in a shorter timeframe" — a workforce-expansion argument that, if validated across more centers, would meaningfully change the global supply of microsurgical capability.

What this means for international patients today

The practical access question is narrower than the technical achievement. Three patient populations are the most likely to benefit from the HKUMed robotic microsurgery program as of mid-2026.

The first is patients with head-and-neck cancer requiring microvascular reconstruction after tumor removal. For patients who would otherwise face a visible anterior neck scar, the trans-hairline robotic approach offers a meaningfully better cosmetic outcome. The procedure is performed at Queen Mary Hospital under the head and neck surgery and plastic and reconstructive surgery divisions, and overseas referrals are accepted through the hospital's international patient services office. The team has not yet published an explicit price comparison, but the typical all-in cost for a head-and-neck cancer resection with microvascular reconstruction at a Hong Kong public-hospital academic center is roughly 40 to 60 percent of the equivalent admission at a major US academic medical center, before insurance.

The second is patients needing living-donor liver transplantation. Hong Kong has one of the most active living-donor liver transplant programs in the world, with Queen Mary Hospital as a major center. For patients who have a suitable living donor but whose case is technically difficult — for example, a recipient with prior abdominal surgery, or a donor with anatomical variants of the hepatic artery — the robotic platform offers a precision advantage on the hepatic artery anastomosis that may matter most when the anatomy is unforgiving. The waiting list for living-donor liver transplantation in Hong Kong is structured around Hong Kong residents, but the program does accept overseas patients whose donor is also overseas, under specific regulatory arrangements.

The third is patients with lymphoedema (typically upper- or lower-limb chronic swelling after cancer surgery, radiation, or congenital lymphatic disease) who are candidates for super-microsurgical lymphaticovenous anastomosis. The procedure connects functioning lymphatic channels, often smaller than 0.3 mm, to nearby subdermal veins to bypass the obstructed lymphatic system. Manual super-microsurgery is one of the most technically demanding applications of the field, and the robotic platform's motion scaling and tremor filtration are particularly well-suited to it. Lymphoedema is a common late effect of breast cancer treatment (affecting roughly 20 to 30 percent of patients after axillary surgery plus radiation), gynecologic cancer treatment, and melanoma treatment, and the patient population is large.

For patients whose cases are not yet operable manually but might become operable with the robotic platform, the practical first step is a referral to the HKUMed surgery department via Queen Mary Hospital's international patient services. The international office can be reached through the hospital's standard channels, and the surgical team reviews imaging and prior records remotely before committing to an in-person consultation. For mainland Chinese patients, the access path is straightforward via the existing HKUMed collaboration networks with mainland tertiary hospitals. For patients from Southeast Asia, the Middle East, and other regions, the standard medical-tourism infrastructure in Hong Kong applies — which, as our 2026-06-22 Raffles Medical article documents, hit 37,000 international patients across three China hospitals in 2025.

The broader question: is robotic microsurgery a durable change, or a 2026 story that fades?

The honest assessment is that the technology is real and the early clinical data are genuinely strong, but the long-term durability of the change depends on factors that the 48-procedure QMH series cannot resolve. The first is whether the peer-reviewed publication of the series, when it appears, will show the same complication and patency rates that the press briefing announced. The second is whether the cost of the platform — which is substantial, in the same general range as a da Vinci system (low seven figures in US dollar terms) — can be justified by outcome improvements at scale. The third is whether other high-volume microsurgery centers will adopt the platform and replicate the QMH experience. The fourth is whether the training pipeline that the platform enables will expand the global supply of competent microsurgeons in practice, as the HKUMed team hopes.

The Chinese microsurgery community is well-positioned to drive the third question forward. The PLA hospital system, the Fourth Military Medical University (which runs the 3D-printed extravascular stent program at Tangdu Hospital), and the major mainland academic centers all have the case volume and the manual skill base to adopt robotic microsurgery programs rapidly once the platform is approved in mainland China. Whether that happens in 2026, 2027, or 2028 is a regulatory and procurement question, not a clinical one.

The deeper point is that HKUMed and Queen Mary Hospital have, in 13 months and 48 procedures, demonstrated that the combination of inherited Chinese microsurgery skill and a well-designed robotic platform can push the technical ceiling of what any surgeon can reliably accomplish. That is the kind of structural change that tends to be durable, because once surgeons see what is possible with the platform, the manual-only approach starts to look limiting in the cases where it matters most. The broader Chinese medical ecosystem — the military hospital microsurgery training network, the mainland academic microsurgery centers, and the mainland surgical-robotics industry, which our 2026-05-03 spine-surgery robot article covered in detail — is well-positioned to make the platform broadly available if the early QMH results hold up in peer-reviewed publication.

What to watch over the next 12 to 18 months

Three concrete things to watch. First, the peer-reviewed publication of the 48-procedure QMH series, with the full per-procedure data on anastomosis time, blood loss, hospital stay, complication rates, and patency. The HKUMed team has indicated the paper is in preparation; the publication will be the durable reference for the program and the trigger for international referrals to scale up.

Second, whether any mainland Chinese center announces a robotic microsurgery program. The leading candidates are Huashan Hospital (Fudan University, Shanghai), the PLA General Hospital (Beijing), and the Fourth Military Medical University-affiliated Tangdu Hospital (Xi'an), all of which have high-volume manual microsurgery services and existing surgical-robotics infrastructure. A mainland program announcement within the next 12 months would confirm that the QMH results are reproducible at scale.

Third, the broader regulatory approval of dedicated microsurgery robotic platforms in mainland China. The Chinese surgical robotics industry has been developing rapidly, with Microport's Toumai and other domestic platforms competing with the da Vinci ecosystem across general laparoscopic surgery. A dedicated microsurgery platform approved by the NMPA would lower the per-procedure cost and accelerate adoption. The NMPA Center for Medical Device Evaluation has been processing surgical robotics approvals at an increasing rate since 2024, and a microsurgery platform approval within the 2026-2028 window is plausible.

For international patients considering the QMH program today, the most actionable next step is a referral through the HKUMed surgery department. The clinical results to date are strong enough to make the program a reasonable option for patients who have been told elsewhere that their case is not operable, or whose previous surgery has failed. The cost differential between QMH and a comparable US academic admission remains substantial enough that even with travel and lodging, the all-in price is typically lower. The constraint, as with most frontier surgical programs, is that the team reviews cases individually and accepts only those where the robotic approach offers a clear advantage over the manual alternative. For the rest, manual microsurgery at QMH or at a mainland Chinese academic center remains the standard.